Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Wuzhou Zhongheng Raises Money for M&A Fund

publication date: Apr 15, 2014
Guangxi Wuzhou Zhongheng Group will establish a pharma M&A fund with partners that could be as large as $162 million. The partners are Wuzhou Zhongheng’s largest shareholder, Guangxi Zhongheng Industrial, plus Beijing Sensegain Investment and other limited partners. Each partner will contribute a specified proportion once a suitable pharmaceutical investment is identified. The specific proportion is 29% by Zhongheng, 20% by Zhongheng Industrial, and 51% by Sensegain and other investors. More details....

Stock Symbol: (SHA: 600252)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital